Choroidal Response to Novel Spectacle Lens to Control Myopia Progression (CHERRY)

SightGlass Vision

Status: Active, not recruiting

Conditions: Myopia, Progressive

Treatments: Device: Novel spectacle lens design

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT03818880

P/654/18/SG

Details and patient eligibility

About

Diurnal variations in the thickness of the choroid have been reported in the literature, and, more recently, the role of the choroid has been studied with respect to its role in myopia (near-sightedness) progression.

Full description

Diurnal variations in the thickness of the choroid have been reported in the literature , and, more recently, the role of the choroid has been studied with respect to its role in myopia (near-sightedness) progression. SightGlass Vision, Inc is conducting a multi-site, randomized, controlled, interventional study to confirm the efficacy and safety of spectacle lenses designed to inhibit the progression of myopia by reducing image contrast in peripheral vision. CORE is participating as a clinical site in this three year study which aims to compare changes in ocular length and cycloplegic auto-refraction in children randomised to wear one of either two test or one control spectacle lens designs; the CPRO-1802-001 (Cypress_SG) study. The sponsor is interested in conducting choroidal thickness measurements only at CORE's site by inviting those participants who have already been found eligible for the CPRO-1802-001 study to participate in this parallel study.

Enrollment: 10 estimated patients

Sex: All

Ages: 6 to 10 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Participating in the CPRO-1802-001 (Cypress_SG) study at CORE
• Read and signed an Assent and their parent/guardian has signed an information consent letter

Exclusion criteria

• Transient health condition which may affect the eye(s) (e.g. a common cold, active allergies, fatigue, etc;)

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

Treatment

Experimental group

Description:

Subjects wearing novel spectacle lenses will be assessed

Treatment:

Device: Novel spectacle lens design